{"id":"https://openalex.org/W2014175065","doi":"https://doi.org/10.1212/01.wnl.0000095209.59347.79","title":"A2Aantagonists as novel non-dopaminergic therapy for motor dysfunction in PD","display_name":"A2Aantagonists as novel non-dopaminergic therapy for motor dysfunction in PD","alternate_titles":[],"publication_year":2003,"publication_date":"2003-12-09","ids":{"openalex":"https://openalex.org/W2014175065","doi":"https://doi.org/10.1212/01.wnl.0000095209.59347.79","mag":"2014175065","pmid":"https://pubmed.ncbi.nlm.nih.gov/14663007"},"language":"en","primary_location":{"id":"doi:10.1212/01.wnl.0000095209.59347.79","doi":"https://doi.org/10.1212/01.wnl.0000095209.59347.79","is_oa":false,"landing_page_url":"https://doi.org/10.1212/01.wnl.0000095209.59347.79","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2014175065"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5105511214","display_name":"Peter G. Jenner","orcid":"https://orcid.org/0009-0006-0327-7584","observed_orcids":["https://orcid.org/0009-0006-0327-7584"]},"institutions":[{"id":"https://openalex.org/I183935753","display_name":"King's College London","ror":"https://ror.org/0220mzb33","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I183935753"]}],"countries":["GB"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Peter Jenner","raw_affiliation_strings":["From the Neurodegenerative Diseases Research Centre, Guy\u2019s, King\u2019s and St. Thomas\u2019 School of Biomedical Sciences, King\u2019s College, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Neurodegenerative Diseases Research Centre, Guy\u2019s, King\u2019s and St. Thomas\u2019 School of Biomedical Sciences, King\u2019s College, London, UK","institution_ids":["https://openalex.org/I183935753"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5105511214"],"corresponding_institution_ids":["https://openalex.org/I183935753"],"apc_list":null,"apc_paid":null,"fwci":1.0549,"has_fulltext":false,"cited_by_count":115,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.70229008,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":86,"max":98},"biblio":{"volume":"61","issue":"11_suppl_6","first_page":"S32","last_page":"S38"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10919","display_name":"Deep Brain Stimulation and Movement Disorders","score":0.00139999995008111,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/parkinson-s-disease","display_name":"Parkinson's disease","score":0.902999997138977},{"id":"https://openalex.org/keywords/adenosine-a2a-receptor-antagonist","display_name":"adenosine A2A receptor antagonists","score":0.9190000295639038},{"id":"https://openalex.org/keywords/non-dopaminergic-therapy","display_name":"non-dopaminergic therapy","score":0.9470000267028809},{"id":"https://openalex.org/keywords/motor-impairment","display_name":"motor impairment","score":0.9160000085830688},{"id":"https://openalex.org/keywords/dyskinesia","display_name":"dyskinesia","score":0.9409999847412109},{"id":"https://openalex.org/keywords/mptp-induced-parkinsonism","display_name":"MPTP-induced parkinsonism","score":0.7200000286102295},{"id":"https://openalex.org/keywords/l-dopa","display_name":"L-DOPA","score":0.6010000109672546},{"id":"https://openalex.org/keywords/quinpirole","display_name":"quinpirole","score":0.9629999995231628},{"id":"https://openalex.org/keywords/basal-ganglia","display_name":"basal ganglia","score":0.9570000171661377},{"id":"https://openalex.org/keywords/gaba-release","display_name":"GABA release","score":0.6650000214576721},{"id":"https://openalex.org/keywords/acetylcholine-release","display_name":"acetylcholine release","score":0.9800000190734863},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.46299999952316284}],"concepts":[{"id":"https://openalex.org/C2780405171","wikidata":"https://www.wikidata.org/wiki/Q629444","display_name":"Dyskinesia","level":4,"score":0.8233895301818848},{"id":"https://openalex.org/C2778674702","wikidata":"https://www.wikidata.org/wiki/Q239816","display_name":"MPTP","level":4,"score":0.6820062398910522},{"id":"https://openalex.org/C2778296116","wikidata":"https://www.wikidata.org/wiki/Q253187","display_name":"Quinpirole","level":4,"score":0.6294565796852112},{"id":"https://openalex.org/C137183658","wikidata":"https://www.wikidata.org/wiki/Q461076","display_name":"Dopaminergic","level":3,"score":0.6126360893249512},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.5790008306503296},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5498585104942322},{"id":"https://openalex.org/C2778187257","wikidata":"https://www.wikidata.org/wiki/Q464210","display_name":"Basal ganglia","level":3,"score":0.5268895626068115},{"id":"https://openalex.org/C2779734285","wikidata":"https://www.wikidata.org/wiki/Q11085","display_name":"Parkinson's disease","level":3,"score":0.516865074634552},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.512901782989502},{"id":"https://openalex.org/C2780304432","wikidata":"https://www.wikidata.org/wiki/Q300989","display_name":"Levodopa","level":4,"score":0.43823856115341187},{"id":"https://openalex.org/C513476851","wikidata":"https://www.wikidata.org/wiki/Q170304","display_name":"Dopamine","level":2,"score":0.4303813576698303},{"id":"https://openalex.org/C169760540","wikidata":"https://www.wikidata.org/wiki/Q207011","display_name":"Neuroscience","level":1,"score":0.3399885594844818},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3062998354434967},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.2284325361251831},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.1946469247341156},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.14058402180671692},{"id":"https://openalex.org/C529278444","wikidata":"https://www.wikidata.org/wiki/Q47273","display_name":"Central nervous system","level":2,"score":0.12744185328483582}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001479","descriptor_name":"Basal Ganglia","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D001479","descriptor_name":"Basal Ganglia","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D003342","descriptor_name":"Corpus Striatum","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D003342","descriptor_name":"Corpus Striatum","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D004357","descriptor_name":"Drug Synergism","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009043","descriptor_name":"Motor Activity","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D010300","descriptor_name":"Parkinson Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D010300","descriptor_name":"Parkinson Disease","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":true},{"descriptor_ui":"D011687","descriptor_name":"Purines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D018491","descriptor_name":"Dopamine Agonists","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D058917","descriptor_name":"Adenosine A2 Receptor Antagonists","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1212/01.wnl.0000095209.59347.79","doi":"https://doi.org/10.1212/01.wnl.0000095209.59347.79","is_oa":false,"landing_page_url":"https://doi.org/10.1212/01.wnl.0000095209.59347.79","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"},{"id":"pmid:14663007","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/14663007","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"Journal Article"},{"id":"pmh:oai:kclpure.kcl.ac.uk:publications/82613b7b-0414-4864-992f-6a630735d7ad","doi":null,"is_oa":false,"landing_page_url":"https://kclpure.kcl.ac.uk/portal/en/publications/82613b7b-0414-4864-992f-6a630735d7ad","pdf_url":null,"source":{"id":"https://openalex.org/S4306400216","display_name":"Research Portal (King's College London)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I183935753","host_organization_name":"King's College London","host_organization_lineage":["https://openalex.org/I183935753"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Jenner, P 2003, 'A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD', Neurology, vol. 61, no. 11 Suppl 6, pp. S32 - S38.","raw_type":"info:eu-repo/semantics/publishedVersion"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":77,"referenced_works":["https://openalex.org/W5967246","https://openalex.org/W63914962","https://openalex.org/W1241718649","https://openalex.org/W1500797869","https://openalex.org/W1575624112","https://openalex.org/W1844553425","https://openalex.org/W1886164324","https://openalex.org/W1920092337","https://openalex.org/W1946075667","https://openalex.org/W1968943959","https://openalex.org/W1970073512","https://openalex.org/W1974463013","https://openalex.org/W1976882249","https://openalex.org/W1978702620","https://openalex.org/W1982703610","https://openalex.org/W1982827121","https://openalex.org/W1992289692","https://openalex.org/W1995566504","https://openalex.org/W1998013279","https://openalex.org/W2002933217","https://openalex.org/W2006537215","https://openalex.org/W2010206955","https://openalex.org/W2016947344","https://openalex.org/W2018019777","https://openalex.org/W2024943800","https://openalex.org/W2026475932","https://openalex.org/W2030108063","https://openalex.org/W2030257205","https://openalex.org/W2033564079","https://openalex.org/W2034588648","https://openalex.org/W2035725338","https://openalex.org/W2035957340","https://openalex.org/W2038031154","https://openalex.org/W2040241220","https://openalex.org/W2043885800","https://openalex.org/W2049152829","https://openalex.org/W2050351659","https://openalex.org/W2053602738","https://openalex.org/W2055654059","https://openalex.org/W2060588252","https://openalex.org/W2063911036","https://openalex.org/W2069312167","https://openalex.org/W2070194750","https://openalex.org/W2073561633","https://openalex.org/W2073630554","https://openalex.org/W2073684281","https://openalex.org/W2077643386","https://openalex.org/W2078792232","https://openalex.org/W2081963528","https://openalex.org/W2083868750","https://openalex.org/W2087881873","https://openalex.org/W2088525880","https://openalex.org/W2092666379","https://openalex.org/W2095352917","https://openalex.org/W2097235678","https://openalex.org/W2097719090","https://openalex.org/W2122189667","https://openalex.org/W2123240188","https://openalex.org/W2123456748","https://openalex.org/W2130570136","https://openalex.org/W2130876203","https://openalex.org/W2131371182","https://openalex.org/W2136306454","https://openalex.org/W2141364712","https://openalex.org/W2145529172","https://openalex.org/W2161835903","https://openalex.org/W2162348868","https://openalex.org/W2169622817","https://openalex.org/W2173637498","https://openalex.org/W2404487560","https://openalex.org/W2477262263","https://openalex.org/W2506515737","https://openalex.org/W2755499039","https://openalex.org/W2767785037","https://openalex.org/W2950888084","https://openalex.org/W4235730787","https://openalex.org/W4236396139"],"related_works":["https://openalex.org/W2088619016","https://openalex.org/W2037199903","https://openalex.org/W2129076813","https://openalex.org/W2034588648","https://openalex.org/W2026475932","https://openalex.org/W2278469986","https://openalex.org/W2111597060","https://openalex.org/W2416708726","https://openalex.org/W2045678127"],"abstract_inverted_index":{"The":[0,64,142],"future":[1],"management":[2,40,159],"of":[3,25,41,72,140,160],"Parkinson's":[4],"disease":[5,16],"(PD)":[6],"requires":[7],"pharmacologic":[8],"agents":[9],"that":[10,22,146,163],"do":[11],"not":[12],"lose":[13],"efficacy":[14],"with":[15,126,174],"progression":[17],"or":[18,81,176],"induce":[19],"dyskinesia":[20,112],"and":[21,51,61,84,103,128,162],"are":[23,45,67],"free":[24],"other":[26],"dopaminergic":[27],"side":[28],"effects.":[29],"A2A":[30,43,65,97,147],"receptor":[31],"antagonists":[32,66],"may":[33,152],"provide":[34],"an":[35],"opportunity":[36],"to":[37,52,117],"introduce":[38],"nondopaminergic":[39],"PD.":[42],"receptors":[44],"selectively":[46],"localized":[47],"in":[48,69,77,88,107,133,172],"basal":[49],"ganglia":[50],"the":[53,95,129,138,158],"indirect":[54],"output":[55],"pathway":[56],"where":[57],"they":[58,164],"control":[59],"GABA":[60],"acetylcholine":[62],"release.":[63],"effective":[68,154],"rodent":[70],"models":[71],"PD,":[73],"reversing":[74],"motor":[75,101],"deficits":[76],"haloperidol-treated,":[78],"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine":[79],"(MPTP)-treated,":[80],"reserpinized":[82],"mice,":[83],"potentiating":[85],"L-dopa-induced":[86],"rotation":[87],"6-hydroxydopamine-lesioned":[89],"rats":[90],"without":[91,110,136],"inducing":[92],"dyskinesia.":[93,141],"Importantly,":[94],"selective":[96],"antagonist":[98],"KW6002":[99,121],"reverses":[100],"disability":[102],"increases":[104],"locomotor":[105],"activity":[106,125],"MPTP-treated":[108,134],"primates":[109,135],"provoking":[111],"established":[113],"by":[114],"previous":[115],"exposure":[116],"L-dopa.":[118],"In":[119],"addition,":[120],"shows":[122],"additive":[123],"antiparkinsonian":[124],"L-dopa":[127,175],"D2":[130],"agonist":[131,178],"quinpirole":[132],"enhancing":[137],"intensity":[139],"data":[143],"available":[144],"suggest":[145],"antagonists,":[148],"such":[149],"as":[150,155],"KW6002,":[151],"be":[153],"monotherapy":[156],"for":[157],"PD":[161],"will":[165],"also":[166],"produce":[167],"additional":[168],"benefit":[169],"when":[170],"administered":[171],"combination":[173],"dopamine":[177],"therapy.":[179]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2014175065","counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":4},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":6},{"year":2016,"cited_by_count":6},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":5},{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":5}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
